NCT03006887View on ClinicalTrials.gov

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 12, 2017

Primary Completion Date

April 15, 2020

Study Completion Date

April 15, 2020

Conditions
Solid Tumors
Interventions
DRUG

lenvatinib

lenvatinib capsules

DRUG

pembrolizumab

pembrolizumab intravenous infusion

Trial Locations (1)

Unknown

Eisai Trial Site 1, Chuo-ku

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Co., Ltd.

INDUSTRY

NCT03006887 - Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | Biotech Hunter | Biotech Hunter